CLAIM CARD
Quantitative findings from the meta-analysis demonstrated that SGLT2 inhibitor treatment was associated with a significant reduction in NT-proBNP levels, with a pooled mean reduction of 136.03 pg/ml (95% confidence interval reported). These findings are detailed in the evidence synthesis (Per-Study Endpoint Evidence) alongside individual study-level effect estimates.
Evidence grade: exploratory
Contradiction status: none
Publication: f0b4aa8b-f260-4fc6-8419-dac0b0a34715
Provenance: Derivation Web chain
Citation Support
source_1Movila 2026source_2Borges 2024source_3Jansz 2026source_4Ali 2026source_5Cersosimo 2025